Financial Management Professionals Inc. Buys 199 Shares of Novo Nordisk A/S (NYSE:NVO)

Financial Management Professionals Inc. raised its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 38.9% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 711 shares of the company’s stock after acquiring an additional 199 shares during the period. Financial Management Professionals Inc.’s holdings in Novo Nordisk A/S were worth $91,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of NVO. Pacific Center for Financial Services lifted its stake in Novo Nordisk A/S by 100.0% during the 3rd quarter. Pacific Center for Financial Services now owns 270 shares of the company’s stock valued at $25,000 after acquiring an additional 135 shares during the period. First PREMIER Bank bought a new position in shares of Novo Nordisk A/S in the 1st quarter worth approximately $25,000. CNB Bank bought a new position in shares of Novo Nordisk A/S in the 4th quarter worth approximately $26,000. Tyler Stone Wealth Management lifted its stake in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. Tyler Stone Wealth Management now owns 292 shares of the company’s stock worth $27,000 after purchasing an additional 146 shares during the period. Finally, West Paces Advisors Inc. lifted its stake in shares of Novo Nordisk A/S by 100.0% in the 3rd quarter. West Paces Advisors Inc. now owns 300 shares of the company’s stock worth $27,000 after purchasing an additional 150 shares during the period. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 1.2 %

Novo Nordisk A/S stock opened at $142.74 on Friday. The firm has a 50 day moving average of $135.00 and a 200 day moving average of $123.54. The firm has a market capitalization of $640.55 billion, a price-to-earnings ratio of 49.22, a P/E/G ratio of 1.42 and a beta of 0.41. Novo Nordisk A/S has a 12-month low of $75.56 and a 12-month high of $148.15. The company has a current ratio of 0.70, a quick ratio of 0.50 and a debt-to-equity ratio of 0.17.

Novo Nordisk A/S (NYSE:NVO) last announced its quarterly earnings data on Thursday, May 2nd. The company reported $0.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.77 by $0.06. Novo Nordisk A/S had a net margin of 36.56% and a return on equity of 91.70%. The business had revenue of $9.52 billion during the quarter, compared to analyst estimates of $9.23 billion. As a group, research analysts predict that Novo Nordisk A/S will post 3.41 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on NVO shares. Argus increased their price objective on shares of Novo Nordisk A/S from $125.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, June 10th. The Goldman Sachs Group started coverage on shares of Novo Nordisk A/S in a research note on Thursday, May 30th. They issued a “buy” rating and a $156.00 price objective on the stock. BMO Capital Markets reiterated an “outperform” rating and issued a $163.00 price objective on shares of Novo Nordisk A/S in a research note on Tuesday, June 25th. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Monday, June 17th. Two research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, Novo Nordisk A/S has an average rating of “Moderate Buy” and an average target price of $145.67.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.